3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
54
Biliary Tract Neoplasms
23
Nasopharyngeal Carcinoma
22
Cholangiocarcinoma
22
Carcinoma, Non-Small-Cell Lung
22
Urinary Bladder Neoplasms
18
Breast Neoplasms
18
Neoplasm Metastasis
17
Lung Neoplasms
14
Lymphoma, Large B-Cell, Diffuse
13
Colorectal Neoplasms
12
Carcinoma, Transitional Cell
12
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
8
Ovarian Neoplasms
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Gallbladder Neoplasms
7
Neoplasms
6
Hodgkin Disease
6
Nasopharyngeal Neoplasms
5
Bile Duct Neoplasms
5
Adenocarcinoma
5
Uterine Cervical Neoplasms
4
Locally Advanced Pancreatic Cancer
4
Endometrial Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Adenocarcinoma
3
Osteosarcoma
3
Lymphoma
3
Interventions
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Nivolumab
1
Mitomycin
1
Human Papillomavirus DNA Tests
1
Gemcitabine
1
Fluorouracil
1
Colposcopy
1
Cisplatin
1
Biopsy
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urogenital Diseases
×
Gemcitabine
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled